期刊文献+

前列腺癌细胞miR-191-5p表达变化及其对细胞增殖和凋亡的影响 被引量:3

下载PDF
导出
摘要 目的观察前列腺癌细胞miR-191-5p表达变化,并探讨敲低其表达对前列腺癌细胞增殖和凋亡的影响。方法采用qRT-PCR法检测miR-191-5p在人前列腺癌细胞PC-3、LNCap、DU145和正常前列腺上皮细胞RWPE-1中的表达。将人前列腺癌细胞PC-3随机分为敲低组和对照组,参照Lipofectamine RNAi max试剂说明书分别转染miR-191-5p inhibitor、NC inhibitor,采用qRT-PCR法检测两组转染48 h时miR-191-5p表达,CCK-8法检测两组转染24 h再培养6、24、48、72、96 h时细胞增殖能力,流式细胞术检测两组转染24 h时细胞周期比例及细胞凋亡比例。结果人前列腺癌细胞PC-3、LNCap、DU145中miR-191-5p相对表达量均高于正常前列腺上皮细胞RWPE-1(P均<0.01)。敲低组与对照组miR-191-5p相对表达量分别为0.27±0.09、1.00±0.02,敲低组明显低于对照组(P<0.01)。两组转染24 h再培养6 h细胞增殖能力比较差异无统计学意义(P>0.05),敲低组转染24 h再培养24、48、72、96 h时细胞增殖能力均低于对照组(P<0.05或<0.01)。敲低组G_0/G_1期细胞比例高于对照组,S期细胞比例低于对照组(P<0.05或<0.01);两组G_2/M期细胞比例比较差异无统计学意义(P>0.05)。敲低组与对照组细胞凋亡比例分别为(16.67±0.97)%、(9.27±0.85)%,两组比较P<0.01。结论前列腺癌细胞中miR-191-5p表达升高;敲低miR-191-5p表达可抑制前列腺癌细胞增殖并促进其凋亡。
出处 《山东医药》 CAS 2018年第8期51-53,共3页 Shandong Medical Journal
基金 海南省卫生厅医学科研重点课题(琼卫2013重点-04)
  • 相关文献

参考文献1

二级参考文献104

  • 1Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, etal. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer2015; 136: E359-86.
  • 2Roobol M J, Carlsson SV. Risk stratification in prostate cancer screening. Nat Rev Urol2013; 10: 38-48.
  • 3Prensner JR, Rubin MA, Wei JT, Chinnaiyan AM. Beyond PSA: the next generation of prostate cancer biomarkers. Sci Transl Med 2012; 4: 127rv3.
  • 4Pienta K J, Walia G, Simons JW, Soule HR. Beyond the androgen receptor: new approaches to treating metastatic prostate cancer. Report of the 2013 Prouts Neck Prostate Cancer Meeting. Prostate 2014; 74: 314-20.
  • 5De Marzo AM, Platz EA, Sutcliffe S, Xu J, Gronberg H, etal. Inflammation in prostate carcinogenesis. Nat Rev Cancer 2007; 7: 256-69.
  • 6Shen MM, Abate-Shen C. Molecular genetics of prostate cancer: new prospects for old challenges. Genes Dev2010; 24: 1967-2000.
  • 7Van der Kwast TH, Roobol MJ. Defining the threshold for significant versus insignificant prostate cancer. Nat Rev Urol 2013; 10: 473-82.
  • 8Attard G, Parker C, Eeles RA, Schroder F, Tomlins SA, et al. Prostate cancer. Lancet 2016; 387: 70-82.
  • 9Trock BJ. Circulating biomarkers for discriminating indolent from aggressive disease in prostate cancer active surveillance. Curr Opin Urol 2014; 24: 293-302.
  • 10Epstein J I, Feng Z, Trock B J, Pierorazio PM. Upgrading and downgrading of prostate cancer from biopsy to radical prostatectomy: incidence and predictive factors using the modified Gleason grading system and factoring in tertiary grades. Eur Urol 2012; 61: 1019-24.

共引文献5

同被引文献35

引证文献3

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部